News
LQDA
12.79
-1.46%
-0.19
Analysts’ Top Healthcare Picks: Qiagen (QGEN), Eli Lilly & Co (LLY)
TipRanks · 4d ago
Weekly Report: what happened at LQDA last week (0422-0426)?
Weekly Report · 5d ago
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
NASDAQ · 04/26 14:00
Commit To Buy Liquidia Corp At $10, Earn 28% Annualized Using Options
NASDAQ · 04/25 15:28
Jim Cramer: You're 'Dice Rolling' With This Biopharma Stock, But Vista Energy Is 'A Good Situation'
Jim Cramer recommended buying Cloudflare, Inc. On CNBC's "Mad Money Lightning Round" He said Axon Enterprise is still good, and he likes First Solar. Cramer said no to Astera Labs, Inc., and Crown Castle Inc. He also said he would like to own Vista Energy.
Benzinga · 04/25 12:18
Weekly Report: what happened at LQDA last week (0415-0419)?
Weekly Report · 04/22 11:06
Notable Thursday Option Activity: ANF, LQDA, ALLY
NASDAQ · 04/18 19:21
Weekly Report: what happened at LQDA last week (0408-0412)?
Weekly Report · 04/15 10:58
Buy Rating for Liquidia Technologies: Innovation and Market Potential Drive Strong Investment Case
TipRanks · 04/10 10:55
Weekly Report: what happened at LQDA last week (0401-0405)?
Weekly Report · 04/08 11:03
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)
TipRanks · 04/02 09:11
The Analyst Landscape: 5 Takes On Liquidia
Liquidia Corp is a biopharmaceutical company focused on the treatment of pulmonary hypertension. Liquidia has been analyzed by 5 analysts in the last three months. The company has an average price target of $28.8. The 12-month price targets assessed by analysts reveal a range of perspectives from bullish to bearish.
Benzinga · 04/01 18:00
BUZZ-U.S. STOCKS ON THE MOVE-Eiger BioPharmaceuticals, Reddit, US energy sector
Stronger-than-expected manufacturing data propped up Treasury yields and tempered expectations of a rate cut in June. The Dow Jones Industrial Average was down 0.75% in midday trading on Monday. The top three S&P 500 percentage gainers were Micron Technology, Wynn Resorts.
Reuters · 04/01 17:47
BUZZ-U.S. STOCKS ON THE MOVE-Trump Media & Technology, Semtech, General Dynamics
The tech-heavy Nasdaq outpaced Wall Street peers on Monday as megacap growth stocks gained on hopes of an early rate cut by the Fed. The Dow Jones Industrial Average was down 0.63% at 39,555.06. The top three S&P 500 percentage gainers were Micron Technology, Wynn Resorts.
Reuters · 04/01 15:50
Liquidia Price Target Maintained With a $28.00/Share by Needham
Dow Jones · 04/01 14:37
Buy Rating Justified by Favorable Legal Outcomes and Imminent FDA Decision for Liquidia Technologies’ Yutrepia
TipRanks · 04/01 14:35
Needham Reiterates Buy on Liquidia, Maintains $28 Price Target
Benzinga · 04/01 14:27
BUZZ-U.S. STOCKS ON THE MOVE-Guess, Crypto stocks, Liquidia
The S&P 500 and the Nasdaq were set to open slightly higher on Monday. The latest inflation print showing moderating consumer prices bolstered hopes of an early interest rate cut by the Federal Reserve. The top three NYSE percentage gainers premarket were Doma Holdings, Guess and Spirit Airlines.
Reuters · 04/01 13:24
BUZZ-Liquidia Corp rises on plans to seek full approval for blood disorder drug
Liquidia Corp said it can seek full approval for its blood pressure drug. Shares of drug developer rise 7.5% to $15.85 premarket. U.S. District court of Delaware set aside the patent infringement lawsuit. Drug was granted tentative approval in 2021 to treat pulmonary arterial hypertension.
Reuters · 04/01 12:24
Weekly Report: what happened at LQDA last week (0325-0329)?
Weekly Report · 04/01 11:01
More
Webull provides a variety of real-time LQDA stock news. You can receive the latest news about Liquidia Corporation through multiple platforms. This information may help you make smarter investment decisions.
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.